Skip to main content
search

A leading large biotech company engaged Certara to manage and streamline the development and annual updates of up to 15 Investigator’s Brochures (IBs) — critical regulatory documents summarizing clinical and nonclinical data for investigational drugs. Certara’s dedicated project manager introduced centralized oversight, real-time dashboards, and optimized workflows, resulting in improved team alignment, reduced delays, and enhanced submission readiness.

Background

Investigator’s Brochures are essential in drug development, providing regulatory agencies and clinical investigators with a comprehensive summary of clinical and nonclinical data. Managing multiple IBs simultaneously presents significant challenges — from coordinating cross-functional teams to maintaining version control and meeting submission deadlines. This large biotech faced inefficiencies, poor visibility, and regulatory risk due to fragmented processes. Certara’s project management expertise brought structure, efficiency, and compliance to the process, enabling the client to meet timelines with greater confidence and expand Certara’s role into additional oversight responsibilities.

Customer challenge

A leading biotech company faced growing pressure to manage the development and annual updates of up to 15 Investigator’s Brochures (IBs) simultaneously—essential regulatory documents that summarize clinical and nonclinical data for investigational drugs.

These updates required input from cross-functional teams, strict version control, and tight alignment with submission timelines.

Challenges included:

  • Poor visibility into IB statuses and deliverables
  • Unclear roles and responsibilities across stakeholders
  • Frequent delays, heightening regulatory risk
  • Ineffective communication of submission risks
  • No centralized system for managing workflows

The volume and complexity made manual tracking and ad hoc coordination unsustainable, compromising compliance and efficiency.

Certara support

In October 2024, the client engaged Certara to lead nonclinical project management for IB development. A dedicated project manager implemented structured oversight and streamlined workflows to ensure timely, accurate, and compliant submissions.

Key Actions:

  • Centralized Oversight of all IBs to align timelines and deliverables
  • Custom Dashboards for real-time status tracking across programs
  • Cross-Functional Leadership to ensure clarity, accountability, and timely follow-through
  • Training & Mentorship to empower the nonclinical writing team
  • Proactive Risk Management to identify submission risks early
  • Workflow Optimization using SharePoint and process improvements

Certara Services

  • Project Management

Client Impact

  • Reduced IB submission delays and improved tracking
  • Increased team alignment and meeting efficiency
  • Empowered writing staff with training and mentorship
  • Enhanced submission readiness through improved workflows
  • Strengthened client confidence, expanding Certara’s role to include nonclinical DSUR oversight

"Afton is proactive, engaged… the annual IB update process is much more manageable due to her ongoing support"

-Associate Director

FAQs

What challenges do large biotech companies face in managing multiple Investigator's Brochure’s (IB)?

1. What challenges do large biotech companies face in managing multiple Investigator’s Brochure’s (IB)?

How did Certara help this large biotech improve Investigator's Brochure (IB) management?

Certara provided dedicated project management support, centralizing oversight for up to 15 IBs, implementing real-time dashboards, streamlining workflows, and leading cross-functional coordination. This approach improved team alignment, reduced submission delays, and strengthened regulatory readiness.

What tools and processes were implemented to streamline Investigator's Brochure (IB) updates?

What tools and processes were implemented to streamline Investigator’s Brochure (IB) updates?

What was the impact of Certara’s project management expertise on Investigator's Brochure (IB) submissions?

The client experienced fewer submission delays, greater clarity in roles and responsibilities, improved communication of risks, and higher team productivity. Certara’s success also led to expanded responsibilities, including oversight of nonclinical Development Safety Update Reports (DSURs).

Which therapeutic areas did this project cover?

The IBs supported investigational drugs in oncology, rare diseases, immunology, and infectious diseases, reflecting the client’s diverse development pipeline.

At which stages of drug development can project management for regulatory documents add value?

At which stages of drug development can project management for regulatory documents add value?

How does improved Investigator's Brochure (IB) management reduce regulatory risk?

By centralizing oversight, standardizing workflows, and tracking progress in real-time, companies can identify potential issues early, address them proactively, and meet submission deadlines with greater confidence, reducing the chance of regulatory delays.

Contact us